Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels

Journal of the American College of Cardiology

Volumn 48, Issue 9, 2006, Pages 1774-1781

  Davidson, Michael H ^a   McKenney, James M ^b   Shear, Charles L ^c   Revkin, James H ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FLATULENCE; GASTROINTESTINAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTICLE SIZE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLINES;

EID: 33750477286     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.06.067     Document Type: Article

References (22)

1. Brewer Jr. H.B. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 92 (2003) 23-29K
2. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
3. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., and Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
4. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
5. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 5 (1994) 339-349
6. Hayek T., Azrolan N., Verdery R.B., et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J Clin Invest 92 (1993) 1143-1152
7. Guerin M., Le Goff W., Lassel T.S., Van Tol A., Steiner G., and Chapman M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 21 (2001) 282-288
8. Sugano M., Makino N., Sawada S., et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273 (1998) 5033-5036
9. Rittershaus C.W., Miller D.P., Thomas L.J., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2106-2112
10. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
11. Morehouse L.A., Sugarman E.D., Bourassa P.A., and Milici A.J. The CETP-inhibitor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits (2004) Presented at the XVth International Symposium on Drugs Affecting Lipid Metabolism. Venice, Italy; October 24-27
12. Clark R.W., Sutfin T.A., Ruggeri R.B., et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
13. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
14. Bell T.J. Statistical Analysis of NHANES III Data (2000), Research Triangle Institute, Research Triangle Park, NC
15. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
16. Otvos J.D., Jeyarajah E.J., and Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 37 (1991) 377-386
17. Ruberg S.J. Dose response studies. II. Analysis and interpretation. J Biopharm Stat 5 (1995) 15-42
18. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
19. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
20. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
21. Rosenson R.S. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 118 (2005) 1067-1077
22. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 285 (2001) 2486-2497